The company will now seek final approval from NCLT, Mumbai Bench, and upon its receipt, OneSource will proceed to seek listing approvals from the BSE and NSE
A new initiative to contribute to enhancing drug discovery capabilities in the field of gene and cell therapy in Japan
The partnership will provide health plans with an out-of-the-box compliance solution for CMS-9115 and CMS-0057 rules
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
For the 2024 outlook, sales growth is now expected to be 22-28% at CER
Contepo offers a unique mechanism of action and has the potential to address increasing antibiotic resistance and gaps in the current antibiotic treatment landscape
This transaction is the third acquisition by three different Japanese players in this segment
Protein research is key to advancing our understanding of human biology and delivering on the promise of precision medicine
Directs officials to ensure that challenges hampering their effective implementation are resolved early in coordination with states
Enhanced collaboration under the Memorandum of Cooperation (MoC) between India and Japan in medical product regulations
Subscribe To Our Newsletter & Stay Updated
